DNA-binding protein (DBP)

DNA-binding proteins (DBPs) represent a broad and diverse class of proteins characterized by their ability to bind to specific or non-specific sequences of DNA to regulate essential cellular processes. This category encompasses transcription factors, histones, polymerases, and nucleases, all of which are critical for DNA replication, repair, and the regulation of gene expression (UniProt, 2023). Within the nucleus, these proteins interact with the major or minor grooves of the DNA double helix through specialized structural motifs like zinc fingers, leucine zippers, and helix-turn-helix domains (NIH, 2021). Dysregulation or mutation of specific DBPs is a central driver in many diseases; for example, mutations in the tumor suppressor p53 are found in over 50% of human cancers, and the overexpression of oncogenic transcription factors like MYC facilitates uncontrolled cell proliferation (Nature Reviews Cancer, 2021). Historically, many DNA-binding proteins were considered "undruggable" due to their lack of traditional deep binding pockets, but recent pharmacological advancements have successfully targeted them using ligand-mediated modulation (e.g., steroid receptors) or innovative approaches like proteolysis-targeting chimeras (PROTACs) (PubMed, 2022). While they are high-value therapeutic targets, the functional diversity of this class requires highly specific strategies to avoid widespread genomic instability or systemic toxicity.

Other names

DNA binding factorNucleic acid-binding proteinGene regulatory proteinChromatin-associated protein

Competitive antagonism of ligand-binding domains, induction of targeted protein degradation (PROTACs), inhibition of DNA-binding domain interaction, allosteric modulation, and inhibition of enzymatic activity (e.g., polymerases or helicases).